Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.61 |
| ▸ | AKT2 | P31751 | 10/20 | 0.61 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351719 | 0.87 | AKT1 (0.63) | AKT1AKT2AKT3CYP2D6CCR5 | |
| SCHEMBL5313797 | 0.80 | AKT1 (0.60) | AKT1AKT2AKT3CYP2D6CCR5 | |
| SCHEMBL5312143 | 0.79 | AKT1 (0.71) | AKT1AKT2AKT3 | |
| SCHEMBL5259020 | 0.79 | AKT1 (0.71) | AKT1AKT2AKT3 | |
| SCHEMBL7586080 | 0.79 | CCR5 (0.67) | AKT1AKT2CYP2D6CCR5LMNA | |
| SCHEMBL5310128 | 0.79 | AKT1 (0.72) | AKT1AKT2AKT3LMNATSHR | |
| SCHEMBL5314880 | 0.78 | AKT1 (0.58) | AKT1AKT2AKT3CYP2D6CCR5 | |
| SCHEMBL4386805 | 0.77 | AKT1 (0.70) | AKT1AKT2AKT3 | |
| SCHEMBL4371234 | 0.77 | AKT1 (0.68) | AKT1AKT2AKT3LMNATSHR | |
| SCHEMBL4373663 | 0.77 | AKT1 (0.75) | AKT1AKT2AKT3CYP2D6CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | claimed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | claimed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1496896-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050222155-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2005-10-06 | — | — | US | disclosed |
| EP-1496896-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003086394-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222155-A1 | Inhibitors of akt activity | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.